Michael Farkouh, MD, Director of Clinical Trials and Associate Professor of Medicine, Mount Sinai School of Medicine, says that there are many strategies to both prevent and control diabetes mellitus, but he notes that obesity prevention is key.
Michael Farkouh, MD, Director of Clinical Trials and Associate Professor of Medicine, Mount Sinai School of Medicine, says that there are many strategies to both prevent and control diabetes mellitus, but he notes that obesity prevention is key.
Diet and exercise are crucial to prevent cardiovascular disease, as well as diabetes. Dr Farkouh also says that drugs, in particular the GLP-1 agonist liraglutide, will be helpful in treating diabetes, but also preventing diabetes with considerable weight loss is crucial.
This video was taken at the American College of Cardiology's 62nd Annual Scientific Session & Expo in San Francisco, CA, on March 11, 2013.
Exploring Pharmaceutical Innovations, Trust, and Access With CVS Health's CMO
July 11th 2024On this episode of Managed Care Cast, we're talking with the chief medical officer of CVS Health about recent pharmaceutical innovations, patient-provider relationships, and strategies to reduce drug costs.
Listen
Managing Skin Conditions: Highlighting Ruxolitinib Cream, Phototherapy Efficacy and Cost
April 8th 2025Research presented at the 2025 Academy of Managed Care Pharmacy annual meeting analyzed real-world treatment outcomes for dermatologic conditions, specifically highlighting the efficacy of ruxolitinib cream for atopic dermatitis and the potential for phototherapy to delay costly biologic initiation.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Safety and Efficacy Updates for Asthma and Urticaria Therapies
April 5th 2025The long-term safety and efficacy of omalizumab, alongside promising phase 3 trial results that demonstrated the efficacy and favorable hematological safety profile of remibrutinib, were highlighted at the 2025 American Academy of Allergy, Asthma & Immunology/World Allergy Organization Joint Congress.
Read More